G1 Therapeutics, Inc. (GTHX)

NASDAQ: GTHX · IEX Real-Time Price · USD
2.64
-0.15 (-5.38%)
At close: Mar 28, 2023, 4:00 PM
2.71
+0.07 (2.65%)
Pre-market: Mar 29, 2023, 6:22 AM EDT
-5.38%
Market Cap 136.38M
Revenue (ttm) 51.30M
Net Income (ttm) -147.56M
Shares Out 51.66M
EPS (ttm) -3.38
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 690,723
Open 2.76
Previous Close 2.79
Day's Range 2.61 - 2.83
52-Week Range 2.55 - 17.49
Beta 1.82
Analysts Buy
Price Target 14.11 (+434.47%)
Earnings Date May 3, 2023

About GTHX

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 17, 2017
Employees 148
Stock Exchange NASDAQ
Ticker Symbol GTHX
Full Company Profile

Financial Performance

In 2022, GTHX's revenue was $51.30 million, an increase of 62.98% compared to the previous year's $31.48 million. Losses were -$147.56 million, -0.53% less than in 2021.

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for GTHX stock is "Buy." The 12-month stock price forecast is $14.11, which is an increase of 434.47% from the latest price.

Price Target
$14.11
(434.47% upside)
Analyst Consensus: Buy
Stock Forecasts

News

G1 Therapeutics (GTHX) Reports Q4 Loss, Tops Revenue Estimates

G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 14.12% and 6.64%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

3 weeks ago - Zacks Investment Research

G1 Therapeutics Provides Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights

- Achieved $31.3 Million in Net Revenue from Sales of COSELA® (trilaciclib) for Full Year 2022, Representing 182% Growth Over 2021; Provided 2023 Net COSELA Revenue Guidance of $50 to $60 Million -

3 weeks ago - GlobeNewsWire

G1 Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference

RESEARCH TRIANGLE PARK, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that on March 7th, 2023, at 10:30 AM EST, G1'...

1 month ago - GlobeNewsWire

G1 Therapeutics to Release Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 1, 2023

RESEARCH TRIANGLE PARK, N.C., Feb. 22, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporat...

1 month ago - GlobeNewsWire

G1 Therapeutics (GTHX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

G1 Therapeutics (GTHX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Why Is G1 Therapeutics (GTHX) Stock Down 52% Today?

G1 Therapeutics (NASDAQ: GTHX) stock is falling on Monday after the company released results from a Phase 3 clinical trial. The bad news bringing GTHX stock down today is the company choosing to end ...

1 month ago - InvestorPlace

G1 Therapeutics Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with FOLFOXIRI + Bevacizumab for Metastatic Colorectal Cancer (CRC) (PRESERVE 1)

- PRESERVE 1 Achieved its Co-Primary Endpoints Showing Statistically Significant Reductions in Occurrence of Severe Neutropenia During Induction and Duration of Severe Neutropenia in Cycles 1 Through ...

1 month ago - GlobeNewsWire

First Prescription for COSELA® (trilaciclib) Issued in China

- COSELA®, the world's first and only myeloprotection drug, was prescribed in Jilin Cancer Hospital on January 28, 2023 - Simcere delivers drug to patients in 908 days from execution of license agreem...

1 month ago - PRNewsWire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Feb. 01, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercis...

1 month ago - GlobeNewsWire

G1 Therapeutics to Participate in the Virtual 2023 B. Riley Securities 3rd Annual Oncology Conference

RESEARCH TRIANGLE PARK, N.C., Jan. 11, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that on January 19th, 2023, at 11:30 AM EST, ...

2 months ago - GlobeNewsWire

G1 Therapeutics Announces Upcoming 2023 Readouts from its Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib

- Initial Results from Pivotal Phase 3 PRESERVE 1 Trial in Colorectal Cancer Expected in February 2023; Positive Results Would Initiate Regulatory Interactions for Label Expansion -

2 months ago - GlobeNewsWire

G1 Therapeutics Provides Initial Update on Phase 2 Bladder Cancer Trial; Progression Free Survival (PFS) Data Expected in Mid-2023

RESEARCH TRIANGLE PARK, N.C., Jan. 04, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today provided an initial update on PRESERVE 3, an ongoing Ph...

2 months ago - GlobeNewsWire

G1 Therapeutics to Participate in the 41st Annual J.P. Morgan Conference

RESEARCH TRIANGLE PARK, N.C., Jan. 03, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that on January 11, 2023, at 1:30 PM PST, G1'...

3 months ago - GlobeNewsWire

Initial Results from Phase 2 Mechanism of Action Trial in Early-Stage Triple Negative Breast Cancer Show that a Single Dose of Trilaciclib Favorably Alters the Tumor Microenvironment

RESEARCH TRIANGLE PARK, N.C., Dec. 07, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today provided initial results from a 24 patient Phase 2 mech...

3 months ago - GlobeNewsWire

G1 Therapeutics to Participate in the Virtual Evercore ISI HealthCONx Conference

RESEARCH TRIANGLE PARK, N.C., Nov. 23, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that Jack Bailey, G1's Chief Executive Office...

4 months ago - GlobeNewsWire

G1 Therapeutics Announces Closing of Offering of Common Stock

RESEARCH TRIANGLE PARK, N.C., Nov. 22, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the closing of an underwritten public offerin...

4 months ago - GlobeNewsWire

G1 Therapeutics Announces Pricing of Offering of Common Stock

RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the pricing of an underwritten public offerin...

4 months ago - GlobeNewsWire

G1 Therapeutics Announces Proposed Public Offering of Common Stock

RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that it has commenced an underwritten public ...

4 months ago - GlobeNewsWire

G1 Therapeutics (GTHX) Reports Q3 Loss, Tops Revenue Estimates

G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 7.81% and 4.14%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

G1 Therapeutics Provides Third Quarter 2022 Financial Results and Operational Highlights

- Achieved $23.6 million in Total Revenue in the Third Quarter of 2022 Including $8.3 million in Net Revenue from Sales of COSELA® (trilaciclib) -

5 months ago - GlobeNewsWire

Initial Results from Phase 2 Trial Demonstrate Potential of Trilaciclib to Reduce Adverse Events Related to an Antibody Drug Conjugate (ADC)

- Data Suggest On-Target Effect of Trilaciclib May Reduce Rates of Myelosuppression, Diarrhea, and Potentially Alopecia Associated with Sacituzumab Govitecan-Hziy - - Data Suggest On-Target Effect of ...

5 months ago - GlobeNewsWire

Is G1 Therapeutics (GTHX) Stock Outpacing Its Medical Peers This Year?

Here is how G1 Therapeutics (GTHX) and HealthEquity (HQY) have performed compared to their sector so far this year.

5 months ago - Zacks Investment Research

G1 Therapeutics Announces Investigator Initiated Study of Trilaciclib and Lurbinectedin in Patients with Extensive Stage Small Cell Lung Cancer

RESEARCH TRIANGLE PARK, N.C., Oct. 26, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that it is supporting a Phase 2 investigator ...

5 months ago - GlobeNewsWire

G1 Therapeutics to Release Third Quarter 2022 Financial Results and Provide Business Update on November 2, 2022

RESEARCH TRIANGLE PARK, N.C., Oct. 19, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporat...

5 months ago - GlobeNewsWire

Is G1 Therapeutics (GTHX) Outperforming Other Medical Stocks This Year?

Here is how G1 Therapeutics (GTHX) and HealthEquity (HQY) have performed compared to their sector so far this year.

5 months ago - Zacks Investment Research